About: Horses for courses? Assessing the potential value of a surrogate, point‐of‐care test for SARS‐CoV‐2 epidemic control

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Horses for courses? Assessing the potential value of a surrogate, point‐of‐care test for SARS‐CoV‐2 epidemic control Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Horses for courses? Assessing the potential value of a surrogate, point‐of‐care test for SARS‐CoV‐2 epidemic control
Creator	Peacock, Sharon Williams, Sarah Huntley, Catherine Ismail, Sharif Post, Nathan Rigby, \| Shrotri, Madhumita
Source	Medline; PMC
abstract	Point‐of‐care tests (POCTs) offer considerable potential for improving clinical and public health management of COVID‐19 by providing timely information to guide decision‐making, but data on real‐world performance are in short supply. Besides SARS‐CoV‐2‐specific tests, there is growing interest in the role of surrogate (non‐specific) tests such as FebriDx, a biochemical POCT which can be used to distinguish viral from bacterial infection in patients with influenza‐like illnesses. This short report assesses what is currently known about FebriDx performance across settings and populations by comparison with some of the more intensively evaluated SARS‐CoV‐2‐specific POCTs. While FebriDx shows some potential in supporting triage for early‐stage infection in acute care settings, this is dependent on SARS‐CoV‐2 being the most likely cause for influenza‐like illnesses, with reduction in discriminatory power when COVID‐19 case numbers are low, and when co‐circulating viral respiratory infections become more prevalent during the autumn and winter. Too little is currently known about its performance in primary care and the community to support use in these contexts, and further evaluation is needed. Reliable SARS CoV2‐specific POCTs—when they become available—are likely to rapidly overtake surrogates as the preferred option given the greater specificity they provide.
has issue date	2020-08-06(xsd:dateTime)
bibo:doi	10.1111/irv.12796
bibo:pmid	32767548
has license	cc-by
sha1sum (hex)	f8499e80e37106238ed93c0fc82a183c735275db
schema:url	https://doi.org/10.1111/irv.12796
resource representing a document's title	Horses for courses? Assessing the potential value of a surrogate, point‐of‐care test for SARS‐CoV‐2 epidemic control
has PubMed Central identifier	PMC7436809
has PubMed identifier	32767548
schema:publication	Influenza Other Respir Viruses
resource representing a document's body	covid:f8499e80e37106238ed93c0fc82a183c735275db#body_text
is schema:about of	named entity 'epidemic' named entity 'irv' named entity 'Horses' named entity 'SARS' named entity 'POCT' named entity 'infection' named entity 'sensitivities and specificities' named entity 'SARS-CoV-2' named entity 'infection' named entity 'antibody response' named entity 'POCT' named entity 'viral infections' named entity 'IgM' named entity 'randomised clinical trial' named entity 'England' named entity 'screening tool' named entity 'primary care' named entity 'acute respiratory illnesses' named entity 'SARS-CoV-2' named entity 'false-negative' named entity 'infection' named entity 'screening tests' named entity 'SARS-CoV-2' named entity 'POCT' named entity 'COVID' named entity 'decision-making' named entity 'respiratory infections' named entity 'primary care' named entity 'hospital settings' named entity 'biochemical' named entity 'respiratory viral infections' named entity 'Point-of-care test' named entity 'SARS-CoV-2' named entity 'viruses' named entity 'RT-PCR' named entity 'influenza-like' named entity 'COVID' named entity 'acute care' named entity 'triage' named entity 'SARS-CoV-2' named entity 'infection' named entity 'SARS' named entity 'antigens' named entity 'SARS-CoV-2' named entity 'POCT' named entity 'antibody tests' named entity 'secondary care' named entity 'bacterial infection' named entity 'SARS-CoV-2' named entity 'early-stage' named entity 'clinical diagnosis' named entity 'rapid diagnostic test' named entity 'infection' named entity 'COVID-19 pandemic' named entity 'SARS-CoV-2' named entity 'RT-PCR' named entity 'secondary care' named entity 'antibiotic' named entity 'antibody' named entity 'influenza-like' named entity 'infection' named entity 'serological' named entity 'COVID' named entity 'IgG' named entity 'symptom' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'symptom' named entity 'symptom' named entity 'infection' named entity 'virus' named entity 'primary care' named entity 'epidemic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software